Early nonclinical safety studies should provide information to support which of the following, EXCEPT?

• A. Initial human dose selection
• B. Safe duration of exposure
• C. Information about physiological and toxicological effects
• D. Market potential of the drug

Answer: (D)

Early nonclinical safety studies are designed to inform human risk by identifying how a drug behaves in animals, what doses and exposure durations are likely to be safe, and what physiological or toxicological effects might occur. This information directly supports choosing a starting dose for humans, planning how long exposure can be safely studied in early trials, and understanding which organs or systems might be affected and at what exposure levels. Market potential has nothing to do with safety testing; it’s a business/market question, not a safety or toxicology question. So the item that does not fit with what these studies provide is market potential.